Abstract:Human beta defensins (hBD) are antimicrobial peptides that are produced by epithelial cells, and are components of innate immunity in mucosae. hBD2 and 3 inhibit HIV infection. Based on the properties of these cationic peptides, which inhibit infectious agents by disrupting their negatively-charged membranes or to glycan moieties on their glycoproteins we expected that hBD2 would exert its HIV-suppressive activity by inactivating HIV, binding to its envelope. While we observed some degree of virus inactivation, we found that hBD2 inhibits HIV also after virus entry. Since hBD2 binds to, and triggers signaling via the chemokine receptor CCR6, we tested the hypothesis that CCR6 mediates the antiviral activity of hBD2. Three lines of evidence support this hypothesis. First, MIP-3α (CCL20), the chemokine ligand for CCR6, induces antiviral activity. Second, hBD2 loses efficacy when tested in CCR6- cells, both in single cycle and spreading infectivity assays. Third, Bordetella Pertussis toxin, an inhibitor of chemokine receptor -mediated intracellular signaling, abrogates the antiviral activity of hBD2 and MIP-3α. Our mechanistic studies show that HIV inhibition occurs at an early stage, prior to completion of reverse transcription. In summary, this is a novel antiviral activity mediated by a chemokine receptor. CCR6 is expressed in cells that are highly relevant to HIV infection, mucosally and in the periphery: memory CCR5+ T lymphocytes, dendritic cells and, based on our data, on LPS-activated macrophages. Interestingly, CCR6 is one of the markers for the Th17 subset of T lymphocytes. Published reports have shown that CCR6+ and Th17 cells are specifically lost in the course of progressive HIV disease or in primate models of AIDS. Thus, a mechanism that protects CCR6 cells from infection may yield novel preventive or therapeutic approaches to HIV infection.

Human Beta Defensin 2 Selectively Inhibits HIV-1 in Highly Permissive CCR6⁺CD4⁺ T Cells

Human Beta-Defensins Induce APOBEC3G Expression by Interacting with Chemokine Receptors, Protecting Highly Susceptible Cells from HIV Infection

Inhibition of HIV Infection in Highly Susceptible Cells with Human beta-Defensins - Induction of APOBEC3G Via Chemokine Receptors

CCR6 Mediates the Intracellular HIV Inhibitory Activity of Human Beta-Defensin 2

Human Beta-Defensin 2 and 3 Inhibit HIV-1 Replication in Macrophages

112 Hbd2 Inhibits HIV Via CCR6, a Receptor Expressed on Memory, Dendritic and Th17 Cells

Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection.

124 CCR6 Ligands Inhibit HIV in Highly Susceptible CD4+CCR6+ T Cells by Inducing APOBEC3G Expression

CCR6 ligands inhibit HIV by inducing APOBEC3G.

Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment

Contribution Of Human Alpha-Defensin 1, 2, And 3 To The Anti-Hiv-1 Activity Of Cd8 Antiviral Factor

alpha-defensins released into stimulated CD8+ T-cell supernatants are likely derived from residual granulocytes within the irradiated allogeneic peripheral blood mononuclear cells used as feeders.

Contribution of Human Α-Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral Factor

Human Neutrophil Alpha-Defensin 4 Inhibits HIV-1 Infection in Vitro.

Multifaceted Mechanisms of HIV-1 Entry Inhibition by Human Α-Defensin.

Anti-HIV Activity of Human Defensin 5 in Primary CD4+ T Cells under Serum-Deprived Conditions is a Consequence of Defensin-Mediated Cytotoxicity

Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.

Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation.

Key Determinants of Human α-Defensin 5 and 6 for Enhancement of HIV Infectivity.

CCR5 Editing by Staphylococcus Aureus Cas9 in Human Primary CD4+ T Cells and Hematopoietic Stem/progenitor Cells Promotes HIV-1 Resistance and CD4+ T Cell Enrichment in Humanized Mice

Simultaneous Zinc-Finger Nuclease Editing of the HIV Coreceptors Ccr5 and Cxcr4 Protects CD4+ T Cells from HIV-1 Infection.